- Home
- MRSN vs SRZN Comparison
MRSN vs SRZN Comparison
Compare MRSN & SRZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRSN
- SRZN
- Stock Information
- Founded
- MRSN 2001
- SRZN 2015
- Country
- MRSN United States
- SRZN United States
- Employees
- MRSN N/A
- SRZN 41
- Industry
- MRSN Biotechnology: Pharmaceutical Preparations
- SRZN Medicinal Chemicals and Botanical Products
- Sector
- MRSN Health Care
- SRZN Health Care
- Exchange
- MRSN Nasdaq
- SRZN Nasdaq
- Market Cap
- MRSN 36.4M
- SRZN 76.5M
- IPO Year
- MRSN 2017
- SRZN N/A
- Fundamental
- Price
- MRSN $0.35
- SRZN $9.75
- Analyst Decision
- MRSN Buy
- SRZN Strong Buy
- Analyst Count
- MRSN 3
- SRZN 2
- Target Price
- MRSN $4.00
- SRZN $38.50
- AVG Volume (30 Days)
- MRSN 3.1M
- SRZN 18.1K
- Earning Date
- MRSN 05-08-2025
- SRZN 05-07-2025
- Dividend Yield
- MRSN N/A
- SRZN N/A
- EPS Growth
- MRSN N/A
- SRZN N/A
- EPS
- MRSN N/A
- SRZN N/A
- Revenue
- MRSN $40,497,000.00
- SRZN $10,655,000.00
- Revenue This Year
- MRSN N/A
- SRZN N/A
- Revenue Next Year
- MRSN N/A
- SRZN N/A
- P/E Ratio
- MRSN N/A
- SRZN N/A
- Revenue Growth
- MRSN 9.88
- SRZN N/A
- 52 Week Low
- MRSN $0.26
- SRZN $6.00
- 52 Week High
- MRSN $3.83
- SRZN $18.17
- Technical
- Relative Strength Index (RSI)
- MRSN 44.90
- SRZN 43.14
- Support Level
- MRSN $0.31
- SRZN $8.84
- Resistance Level
- MRSN $0.40
- SRZN $10.40
- Average True Range (ATR)
- MRSN 0.05
- SRZN 0.79
- MACD
- MRSN 0.01
- SRZN -0.09
- Stochastic Oscillator
- MRSN 68.09
- SRZN 22.26
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates (ADCs) that offer a clinically meaningful benefit for cancer patients with unmet needs. The Company's next-generation ADC platforms include Dolasynthen, which delivers a proprietary auristatin payload, and Immunosynthen, which delivers a proprietary stimulator of interferon genes (STING) agonist payload. Its pipeline includes Emi-Le (XMT-1660), XMT-2056, XMT-2068, and XMT-2175.
About SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).